First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis

Immune checkpoint inhibitors (ICIs) are widely used for first-line cisplatin-ineligible patients with metastatic urothelial carcinoma (mUC). However, whether to use ICIs as monotherapy or in combination with chemotherapy is still uncertain. We retrospectively analyzed cisplatin-ineligible patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Chang-Ting, Su, Po-Jung, Huang, Shih-Yu, Wu, Chia-Che, Wang, Hung-Jen, Cheng, Yuan-Tso, Luo, Hao-Lun, Chen, Chien-Hsu, Liu, Ting-Ting, Huang, Chun-Chieh, Su, Yu-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528941/
https://www.ncbi.nlm.nih.gov/pubmed/36121316
http://dx.doi.org/10.1097/CJI.0000000000000441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528941/
https://www.ncbi.nlm.nih.gov/pubmed/36121316
http://dx.doi.org/10.1097/CJI.0000000000000441

Ejemplares similares